Print（PDF/93KB） Oct. 17, 2019 Corporate

Comments on Acquisition Proposal to Australian Stem Cell and Regenerative Medicine Company

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has withdrawn its offer to acquire Cynata Therapeutics Limited (Head office: Australia), a stem cell and regenerative medicine company, as the parties have been unable to reach mutually agreed on terms on the proposed acquisition. As disclosed on July 19, 2019, Sumitomo Dainippon Pharma had made the proposal for the acquisition of Cynata and was negotiating with Cynata.